The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant infection in vivo

Journal:

Nature Communications

Published:

2025-09-18

DOI:

10.1038/s41467-025-63508-w

Affiliations:

9

Authors:

31

Go to article

Institutions	Authors	Share
DebioPharm S.A., Switzerland	19.000000 19.000000	0.61
Nobelex Biotech, Canada	4.000000	0.13
WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, Sweden	2.500000	0.08
Sygnature Discovery Limited, United Kingdom (UK)	2.000000	0.06
NovAliX, France	2.000000	0.06
University of Liverpool, United Kingdom (UK)	0.500000	0.02
Liverpool Health Partners (LHP), United Kingdom (UK)	0.500000	0.02
UCL, United Kingdom (UK)	0.500000	0.02

Interested in Medical Microbiology?